Completed OBSERVATIONAL NCT01001481

Schizophrenia Treatment Adherence Investigation (STAI)

Clinical Audit and Feedback Program to Determine Risk for Medication Adherence in Outpatients Diagnosed With Schizophrenia in Australia

Sponsor: Janssen-Cilag Pty Ltd

Conditions Schizoaffective Disorder Schizophrenia

Interventions Risk status for medication adherence

Updated 6 times since 2017 Last updated: Apr 8, 2014 Started: Jul 31, 2007 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Janssen-Cilag Pty Ltd leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Pty Ltd

Data source: Janssen-Cilag Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.